Topical Vancomycin Paste Over the Sternal Edge During Cardiac Surgery: Effects of Renal Function and Body Size on Systemic Exposure

•Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal function.•For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning. Intraoperative topical vancomycin has been widely us...

Full description

Saved in:
Bibliographic Details
Published inClinical therapeutics Vol. 47; no. 2; pp. 135 - 142
Main Authors Tsai, Meng-Ta, Hu, Yu-Ning, Roan, Jun-Neng, Kan, Chung-Dann, Wang, Yi-Chen, Luo, Chwan-Yau, Chou, Chen-Hsi
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2025
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal function.•For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning. Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%. Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning. [Display omitted]
AbstractList Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined.PURPOSEIntraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined.Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models.METHODSTopical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models.Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%.FINDINGSSixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%.Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning.IMPLICATIONSPlasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning.
Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m , the chance of vancomycin >10 mg/L is up to 20% to 30%. Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning.
Highlights•Body size and renal status affect plasma exposure after topical sternal vancomycin. •Minimal systemic exposure, even with small body size or impaired renal function. •For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning.
•Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal function.•For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning. Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%. Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning. [Display omitted]
Purpose Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Methods Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Findings Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m 2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m 2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m 2, the chance of vancomycin >10 mg/L is up to 20% to 30%. Implications Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning.
Author Luo, Chwan-Yau
Wang, Yi-Chen
Hu, Yu-Ning
Roan, Jun-Neng
Kan, Chung-Dann
Chou, Chen-Hsi
Tsai, Meng-Ta
Author_xml – sequence: 1
  givenname: Meng-Ta
  surname: Tsai
  fullname: Tsai, Meng-Ta
  organization: Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
– sequence: 2
  givenname: Yu-Ning
  surname: Hu
  fullname: Hu, Yu-Ning
  organization: Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan
– sequence: 3
  givenname: Jun-Neng
  surname: Roan
  fullname: Roan, Jun-Neng
  organization: Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan
– sequence: 4
  givenname: Chung-Dann
  surname: Kan
  fullname: Kan, Chung-Dann
  organization: Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan
– sequence: 5
  givenname: Yi-Chen
  surname: Wang
  fullname: Wang, Yi-Chen
  organization: Division of Cardiovascular Surgery, Department of Surgery, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan
– sequence: 6
  givenname: Chwan-Yau
  surname: Luo
  fullname: Luo, Chwan-Yau
  organization: Division of Cardiovascular Surgery, Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
– sequence: 7
  givenname: Chen-Hsi
  orcidid: 0000-0003-0708-3657
  surname: Chou
  fullname: Chou, Chen-Hsi
  email: chenhsi@mail.ncku.edu.tw
  organization: Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39706762$$D View this record in MEDLINE/PubMed
BookMark eNqNkkFvEzEQhS1URNPCXwBLXLhk8djr3SwHUAkpIFUqIgVxs1x7NjgkdrB3K5YrfxyvUnKohNTTSNY3zzPvzQk58sEjIc-AFcCgerkuzMb57jtGXXDGywKgyOUBmcCsbqYA5bcjMmFQNlPewOyYnKS0ZoyJRvJH5Fg0Navqik_In6uwc0Zv6FftTdgOxnn6SacO6eUNRpp_oMsOo8_Ewq6Qvuuj8ys619E6beiyjyuMwyu6aFs0XaKhpZ9xpM97bzoXPNXe0rfBDnTpfiPND8shy2-doYtfu5D6iI_Jw1ZvEj65rafky_niav5henH5_uP87GJqSll1U2wRZ9C02sjrRguLUEkjRSu1nPGytdZg2zSGAzLNa2khQ1yLqmLImKxLcUpe7HV3MfzsMXVq65LBzUZ7DH1SAsq6qQWXs4w-v4OuQz-6MFKVKAVIAZl6ekv111u0ahfdVsdB_bM3A_UeMDGkFLE9IMDUGKRaq0OQagxSAahccufZvhOzITcOo0rGoTdoXcxGKxvcPTRe39EYuTHtHzhgOmwEKnHF1HI8l_FaeJkPpebj-G_-L3CvEf4CwTLU6w
Cites_doi 10.1016/j.jtcvs.2016.01.060
10.1086/663708
10.1016/j.jtcvs.2014.06.045
10.1016/j.athoracsur.2016.10.020
10.1016/j.jtcvs.2019.11.004
10.1097/BRS.0000000000000465
10.1111/iwj.14074
10.1016/j.jtcvs.2019.11.137
10.1097/BRS.0b013e3181ff2cb1
10.1016/S0022-5223(19)34366-1
10.1016/j.athoracsur.2021.11.012
10.1002/jssc.201500600
10.1111/j.1540-8191.2011.01300.x
10.1016/j.arth.2015.10.015
10.1016/j.surg.2023.05.031
10.1016/S1010-7940(03)00033-2
10.1111/j.1469-0691.2006.01344.x
10.1016/j.athoracsur.2021.09.036
ContentType Journal Article
Copyright 2024 Elsevier Inc.
Elsevier Inc.
Copyright © 2024 Elsevier Inc. All rights reserved.
2024. Elsevier Inc.
Copyright_xml – notice: 2024 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright © 2024 Elsevier Inc. All rights reserved.
– notice: 2024. Elsevier Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88C
88E
8AO
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
KB0
M0S
M0T
M1P
M2O
M7N
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
DOI 10.1016/j.clinthera.2024.11.024
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Healthcare Administration Database
Medical Database
Research Library (ProQuest)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE


Research Library Prep

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1879-114X
EndPage 142
ExternalDocumentID 39706762
10_1016_j_clinthera_2024_11_024
S0149291824003722
1_s2_0_S0149291824003722
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1~.
1~5
29B
4.4
457
4G.
53G
5RE
5VS
6J9
6PF
7-5
71M
7RV
7X7
88E
8AO
8FI
8FJ
8G5
8P~
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABUWG
ABWVN
ABXDB
ABZDS
ACDAQ
ACIEU
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AQUVI
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BENPR
BKEYQ
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
DWQXO
EBS
EFJIC
EFKBS
EJD
EMOBN
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
GNUQQ
GUQSH
HMCUK
HVGLF
HZ~
H~9
IHE
J1W
KOM
M0T
M1P
M2O
M41
MO0
N9A
NAPCQ
O-L
O9-
OAUVE
OD~
OGGZJ
OO0
OZT
P-8
P-9
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
Q38
R2-
ROL
RPZ
SCC
SDF
SDG
SEL
SES
SEW
SPCBC
SSH
SSP
SSZ
SV3
T5K
UHS
UKHRP
WH7
WOW
XOL
Z5R
ZGI
ZXP
~G-
0SF
3V.
AACTN
AAYOK
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
NCXOZ
RIG
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
M7N
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c456t-efee819fac5b9a3de165c53f5a5824fddcef99c21e0a275d19a32a3660e005743
IEDL.DBID 7X7
ISSN 0149-2918
1879-114X
IngestDate Mon Jul 21 11:37:59 EDT 2025
Wed Aug 13 09:10:21 EDT 2025
Mon Jul 21 05:47:28 EDT 2025
Tue Jul 01 04:22:00 EDT 2025
Sat Feb 15 15:52:17 EST 2025
Mon Feb 24 20:12:03 EST 2025
Tue Aug 26 16:32:08 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Systemic exposure
Renal function
Body surface area
Cardiac surgery
Sternum
Topical vancomycin
Language English
License Copyright © 2024 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c456t-efee819fac5b9a3de165c53f5a5824fddcef99c21e0a275d19a32a3660e005743
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0708-3657
PMID 39706762
PQID 3163431531
PQPubID 1226358
PageCount 8
ParticipantIDs proquest_miscellaneous_3147973258
proquest_journals_3163431531
pubmed_primary_39706762
crossref_primary_10_1016_j_clinthera_2024_11_024
elsevier_sciencedirect_doi_10_1016_j_clinthera_2024_11_024
elsevier_clinicalkeyesjournals_1_s2_0_S0149291824003722
elsevier_clinicalkey_doi_10_1016_j_clinthera_2024_11_024
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-02-01
PublicationDateYYYYMMDD 2025-02-01
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bridgewater
PublicationTitle Clinical therapeutics
PublicationTitleAlternate Clin Ther
PublicationYear 2025
Publisher Elsevier Inc
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
References Pervaiz, Chaudhry, Javaid (bib0010) 2019; 5
Khan, Din, Ehsanullah (bib0007) 2019; 30
Johnson, Nessler, Horazdovsky (bib0001) 2017; 32
Servito, Khani-Hanjani, Smith (bib0011) 2022; 114
Lander, Ejiofor, McGurk (bib0016) 2017; 103
Vander Salm, Okike (bib0017) 1989; 98
Lazar, Barlam, Cabral (bib0008) 2011; 26
Mascitti, Edelstein, Fishman (bib0019) 2012; 33
Sweet, Roh, Sliva (bib0018) 2011; 36
Desmond, Lovering, Harle (bib0005) 2003; 23
Javorska, Krcmova, Solichova (bib0013) 2016; 39
Lazar, Salm, Engelman (bib0003) 2016; 152
Donovan, Sino, Paraforos (bib0006) 2022; 114
Kowalewski, Pasierski, Makhoul (bib0002) 2023; 174
Griffin, Teixeira, Ambruso (bib0014) 2021; 161
Zhang, Zhang, Li (bib0012) 2023; 20
Priyanka, Zarbock, Izawa (bib0015) 2021; 162
Armaghani, Menge, Lovejoy (bib0004) 2014; 39
Appelbaum (bib0020) 2006; 12
Lazar, Ketchedjian, Haime (bib0009) 2014; 148
Lazar (10.1016/j.clinthera.2024.11.024_bib0008) 2011; 26
Javorska (10.1016/j.clinthera.2024.11.024_bib0013) 2016; 39
Vander Salm (10.1016/j.clinthera.2024.11.024_bib0017) 1989; 98
Lander (10.1016/j.clinthera.2024.11.024_bib0016) 2017; 103
Desmond (10.1016/j.clinthera.2024.11.024_bib0005) 2003; 23
Mascitti (10.1016/j.clinthera.2024.11.024_bib0019) 2012; 33
Priyanka (10.1016/j.clinthera.2024.11.024_bib0015) 2021; 162
Appelbaum (10.1016/j.clinthera.2024.11.024_bib0020) 2006; 12
Pervaiz (10.1016/j.clinthera.2024.11.024_bib0010) 2019; 5
Zhang (10.1016/j.clinthera.2024.11.024_bib0012) 2023; 20
Servito (10.1016/j.clinthera.2024.11.024_bib0011) 2022; 114
Johnson (10.1016/j.clinthera.2024.11.024_bib0001) 2017; 32
Lazar (10.1016/j.clinthera.2024.11.024_bib0009) 2014; 148
Donovan (10.1016/j.clinthera.2024.11.024_bib0006) 2022; 114
Lazar (10.1016/j.clinthera.2024.11.024_bib0003) 2016; 152
Armaghani (10.1016/j.clinthera.2024.11.024_bib0004) 2014; 39
Griffin (10.1016/j.clinthera.2024.11.024_bib0014) 2021; 161
Sweet (10.1016/j.clinthera.2024.11.024_bib0018) 2011; 36
Kowalewski (10.1016/j.clinthera.2024.11.024_bib0002) 2023; 174
Khan (10.1016/j.clinthera.2024.11.024_bib0007) 2019; 30
References_xml – volume: 36
  start-page: 2084
  year: 2011
  end-page: 2088
  ident: bib0018
  article-title: Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes
  publication-title: Spine
– volume: 33
  start-page: 160
  year: 2012
  end-page: 166
  ident: bib0019
  article-title: Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia
  publication-title: Infect Control Hosp Epidemiol
– volume: 39
  start-page: 6
  year: 2016
  end-page: 20
  ident: bib0013
  article-title: Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography-A review
  publication-title: J Sep Sci
– volume: 23
  start-page: 765
  year: 2003
  end-page: 770
  ident: bib0005
  article-title: Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin
  publication-title: Eur J Cardiothorac Surg
– volume: 114
  start-page: 1555
  year: 2022
  end-page: 1561
  ident: bib0011
  article-title: Topical vancomycin and risk of sternal wound infections: a double-blind randomized controlled trial
  publication-title: Ann Thorac Surg
– volume: 5
  start-page: 015
  year: 2019
  end-page: 018
  ident: bib0010
  article-title: Topical vancomycin in cardiac surgery to reduce sternal wound infections: a randomized controlled trial at a tertiary cardiac care facility
  publication-title: J Surg Surgical Res
– volume: 20
  start-page: 2068
  year: 2023
  end-page: 2074
  ident: bib0012
  article-title: A meta-analysis examined the effect of topical vancomycin application in decreasing sternal wound infections post cardiac surgery
  publication-title: Int Wound J
– volume: 12
  start-page: 16
  year: 2006
  end-page: 23
  ident: bib0020
  article-title: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
  publication-title: Clin Microbiol Infect
– volume: 32
  start-page: 924
  year: 2017
  end-page: 928
  ident: bib0001
  article-title: Serum and wound vancomycin levels after intrawound administration in primary total joint arthroplasty
  publication-title: J Arthroplasty
– volume: 30
  start-page: 83
  year: 2019
  end-page: 86
  ident: bib0007
  article-title: Role of topical vancomycin reduction of sternal wound infection in patients undergoing cardiac surgery
  publication-title: Med Forum Monthly
– volume: 162
  start-page: 143
  year: 2021
  end-page: 151
  ident: bib0015
  article-title: The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients
  publication-title: J Thorac Cardiovasc Surg
– volume: 114
  start-page: 511
  year: 2022
  end-page: 518
  ident: bib0006
  article-title: Topical vancomycin reduces the incidence of deep sternal wound complications after sternotomy
  publication-title: Ann Thorac Surg
– volume: 103
  start-page: 497
  year: 2017
  end-page: 503
  ident: bib0016
  article-title: Vancomycin paste does not reduce the incidence of deep sternal wound infection after cardiac operations
  publication-title: Ann Thorac Surg
– volume: 39
  start-page: 1683
  year: 2014
  end-page: 1687
  ident: bib0004
  article-title: Safety of topical vancomycin for pediatric spinal deformity: non-toxic serum levels with supratherapeutic drain levels
  publication-title: Spine
– volume: 161
  start-page: 1346
  year: 2021
  end-page: 1355
  ident: bib0014
  article-title: Stage 1 acute kidney injury is independently associated with infection following cardiac surgery
  publication-title: J
– volume: 26
  start-page: 461
  year: 2011
  end-page: 465
  ident: bib0008
  article-title: The effect of topical vancomycin applied to sternotomy incisions on postoperative serum vancomycin levels
  publication-title: J Card Surg
– volume: 148
  start-page: 1035
  year: 2014
  end-page: 1038
  ident: bib0009
  article-title: Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections
  publication-title: J Thorac Cardiovasc Surg
– volume: 152
  start-page: 962
  year: 2016
  end-page: 972
  ident: bib0003
  article-title: Prevention and management of sternal wound infections
  publication-title: J Thorac Cardiovasc Surg
– volume: 174
  start-page: 1102
  year: 2023
  end-page: 1112
  ident: bib0002
  article-title: Topical vancomycin for sternal wound infection prophylaxis. A systematic review and updated meta-analysis of over 40,000 cardiac surgery patients
  publication-title: Surgery
– volume: 98
  start-page: 618
  year: 1989
  end-page: 622
  ident: bib0017
  article-title: Reduction of sternal infection by application of topical vancomycin
  publication-title: J Thorac Cardiovasc Surg
– volume: 152
  start-page: 962
  year: 2016
  ident: 10.1016/j.clinthera.2024.11.024_bib0003
  article-title: Prevention and management of sternal wound infections
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/j.jtcvs.2016.01.060
– volume: 33
  start-page: 160
  year: 2012
  ident: 10.1016/j.clinthera.2024.11.024_bib0019
  article-title: Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1086/663708
– volume: 148
  start-page: 1035
  year: 2014
  ident: 10.1016/j.clinthera.2024.11.024_bib0009
  article-title: Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/j.jtcvs.2014.06.045
– volume: 103
  start-page: 497
  year: 2017
  ident: 10.1016/j.clinthera.2024.11.024_bib0016
  article-title: Vancomycin paste does not reduce the incidence of deep sternal wound infection after cardiac operations
  publication-title: Ann Thorac Surg
  doi: 10.1016/j.athoracsur.2016.10.020
– volume: 30
  start-page: 83
  year: 2019
  ident: 10.1016/j.clinthera.2024.11.024_bib0007
  article-title: Role of topical vancomycin reduction of sternal wound infection in patients undergoing cardiac surgery
  publication-title: Med Forum Monthly
– volume: 5
  start-page: 015
  year: 2019
  ident: 10.1016/j.clinthera.2024.11.024_bib0010
  article-title: Topical vancomycin in cardiac surgery to reduce sternal wound infections: a randomized controlled trial at a tertiary cardiac care facility
  publication-title: J Surg Surgical Res
– volume: 161
  start-page: 1346
  year: 2021
  ident: 10.1016/j.clinthera.2024.11.024_bib0014
  article-title: Stage 1 acute kidney injury is independently associated with infection following cardiac surgery
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/j.jtcvs.2019.11.004
– volume: 39
  start-page: 1683
  year: 2014
  ident: 10.1016/j.clinthera.2024.11.024_bib0004
  article-title: Safety of topical vancomycin for pediatric spinal deformity: non-toxic serum levels with supratherapeutic drain levels
  publication-title: Spine
  doi: 10.1097/BRS.0000000000000465
– volume: 20
  start-page: 2068
  year: 2023
  ident: 10.1016/j.clinthera.2024.11.024_bib0012
  article-title: A meta-analysis examined the effect of topical vancomycin application in decreasing sternal wound infections post cardiac surgery
  publication-title: Int Wound J
  doi: 10.1111/iwj.14074
– volume: 162
  start-page: 143
  year: 2021
  ident: 10.1016/j.clinthera.2024.11.024_bib0015
  article-title: The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/j.jtcvs.2019.11.137
– volume: 36
  start-page: 2084
  year: 2011
  ident: 10.1016/j.clinthera.2024.11.024_bib0018
  article-title: Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes
  publication-title: Spine
  doi: 10.1097/BRS.0b013e3181ff2cb1
– volume: 98
  start-page: 618
  year: 1989
  ident: 10.1016/j.clinthera.2024.11.024_bib0017
  article-title: Reduction of sternal infection by application of topical vancomycin
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/S0022-5223(19)34366-1
– volume: 114
  start-page: 1555
  year: 2022
  ident: 10.1016/j.clinthera.2024.11.024_bib0011
  article-title: Topical vancomycin and risk of sternal wound infections: a double-blind randomized controlled trial
  publication-title: Ann Thorac Surg
  doi: 10.1016/j.athoracsur.2021.11.012
– volume: 39
  start-page: 6
  year: 2016
  ident: 10.1016/j.clinthera.2024.11.024_bib0013
  article-title: Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography-A review
  publication-title: J Sep Sci
  doi: 10.1002/jssc.201500600
– volume: 26
  start-page: 461
  year: 2011
  ident: 10.1016/j.clinthera.2024.11.024_bib0008
  article-title: The effect of topical vancomycin applied to sternotomy incisions on postoperative serum vancomycin levels
  publication-title: J Card Surg
  doi: 10.1111/j.1540-8191.2011.01300.x
– volume: 32
  start-page: 924
  year: 2017
  ident: 10.1016/j.clinthera.2024.11.024_bib0001
  article-title: Serum and wound vancomycin levels after intrawound administration in primary total joint arthroplasty
  publication-title: J Arthroplasty
  doi: 10.1016/j.arth.2015.10.015
– volume: 174
  start-page: 1102
  year: 2023
  ident: 10.1016/j.clinthera.2024.11.024_bib0002
  article-title: Topical vancomycin for sternal wound infection prophylaxis. A systematic review and updated meta-analysis of over 40,000 cardiac surgery patients
  publication-title: Surgery
  doi: 10.1016/j.surg.2023.05.031
– volume: 23
  start-page: 765
  year: 2003
  ident: 10.1016/j.clinthera.2024.11.024_bib0005
  article-title: Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin
  publication-title: Eur J Cardiothorac Surg
  doi: 10.1016/S1010-7940(03)00033-2
– volume: 12
  start-page: 16
  issue: Suppl 1
  year: 2006
  ident: 10.1016/j.clinthera.2024.11.024_bib0020
  article-title: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
  publication-title: Clin Microbiol Infect
  doi: 10.1111/j.1469-0691.2006.01344.x
– volume: 114
  start-page: 511
  year: 2022
  ident: 10.1016/j.clinthera.2024.11.024_bib0006
  article-title: Topical vancomycin reduces the incidence of deep sternal wound complications after sternotomy
  publication-title: Ann Thorac Surg
  doi: 10.1016/j.athoracsur.2021.09.036
SSID ssj0003952
Score 2.4452553
Snippet •Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal...
Highlights•Body size and renal status affect plasma exposure after topical sternal vancomycin. •Minimal systemic exposure, even with small body size or...
Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the...
Purpose Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 135
SubjectTerms Administration, Topical
Adults
Aged
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - blood
Anti-Bacterial Agents - pharmacokinetics
Antibiotics
Body Size
Body Surface Area
Cardiac surgery
Cardiac Surgical Procedures - methods
Cardiovascular disease
Chronic illnesses
Coronary vessels
Creatinine
Diabetes
End-stage renal disease
Enzymes
Female
Glomerular Filtration Rate
Heart surgery
Hemodialysis
Humans
Infections
Internal Medicine
Kidney diseases
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - physiopathology
Male
Middle Aged
Patients
Pharmacokinetics
Plasma
Postoperative period
Renal function
Sternum
Sternum - surgery
Surgery
Surgical Wound Infection - prevention & control
Systemic exposure
Topical vancomycin
Vancomycin
Vancomycin - administration & dosage
Vancomycin - blood
Vancomycin - pharmacokinetics
Variables
Wound infection
SummonAdditionalLinks – databaseName: Elsevier SD Freedom Collection
  dbid: .~1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fi9QwEA7HPYgvouev6ikjyD1db9s06bb3pusuh3C6uHtybyFNUlnBdrF74Prgi_-4M03b5dBDwZcW2gkJ-SYzX5uZCWMvtUulEM6GSAVsKBIrwzzDC1IHnmljXGkpG_n8XXp2Id5eyss9NulzYSissrP93qa31rp7Mupmc7RerUYUloS-HfmxoCIqnOywEGPS8pMfuzCPJG9P3SHhkKSvxXhR9mGb54QfilycUDlPLm7yUDcx0NYTze6yOx2FhFd-lPfYnqsO2K3zbpP8gB3NfTnq7TEsd9lVzTEcwXxXqHp7n_1c1mvCCD4i9PWXLTaHuUbY4T0qOOCQYeFrRMPUfnLwpk1phEmrVAYWPqP6FHwF5AbqEj44kp6hsyTAQVcWXtd2C4vVdwf4wBdIXxmYflvX9HPyAbuYTZeTs7A7lCE0yLU2oSudQxZRaiOLXCfWxak0MimllohEaS3Cm-eGxy7SHPGPUYjrJE0jR4mvInnI9qu6co8ZZGkZJfjWxUILY-KiGNOOMpKUoqDDDgMW9UCota-9ofqgtM9qwE4Rdvglo_AWsKwHTPWppWgMFfqHvzcd_6mpa7pF3ahYNVxF6jfFC9jp0PKa7v5bt4e9XqmhpwRZMjI7tI8BezG8xoVPuzm6cvUVyYgxlVqSWcAeeX0cZglJJrKQlD_5n5E9Zbc5HXbchqgfsv3N1yv3DBnYpnjeLrFf3Ukvuw
  priority: 102
  providerName: Elsevier
Title Topical Vancomycin Paste Over the Sternal Edge During Cardiac Surgery: Effects of Renal Function and Body Size on Systemic Exposure
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0149291824003722
https://www.clinicalkey.es/playcontent/1-s2.0-S0149291824003722
https://dx.doi.org/10.1016/j.clinthera.2024.11.024
https://www.ncbi.nlm.nih.gov/pubmed/39706762
https://www.proquest.com/docview/3163431531
https://www.proquest.com/docview/3147973258
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFeEIyPBUZ1SGhPy0gc52svaButCmilWjvUN8uxHTQkkkI6ifLAC_84d_mqkBjw0kiN3UT9nX0_23e_Y-yFslEohDUuUgHjisCEbprgB1IHniitbW4oG_l8Eo0vxdtFuGg33Ko2rLKbE-uJ2pSa9shfBkgc0NmhybxafnGpahSdrrYlNLbYDkmXUUhXvOgXXF6Q1hV3aBXg8tRPfovvoszDOscJF4lcHJGUJxc3eaeb2GfthUb32N2WPsJJg_d9dssWu-z2eXtAvssOpo0U9foQ5pvMquoQDmC6EaleP2A_5-WS8IEPCHv5eY3dYaoQcniPxg34yjBr9KFhaD5aeF2nM8JZbVAaZk029TE06scVlDlcWGo9QkdJYIMqDJyWZg2zq-8W8ItGHP1Kw_DbsqSNyYfscjScn43dtiCDq5FnrVybW4sMIlc6zFIVGOtHoQ6DPFRhwkVuDEKbppr71lMcsfexEVdBFHmWkl5F8IhtF2Vh9xgkUe4FeNf6Qgmt_SyL6TQZCUqWUaFDh3kdEHLZ6G7ILiDtk-yxk4QdrmIkXhyWdIDJLq0UJ0KJvuHfXeM_dbVVO6Ar6cuKS6-OhUvJlCj0Nog5d9hx37PlLA0X-b_H7nd2JfsnbQzdYc_72zjo6SRHFba8pjYiJpmlMHHY48Ye-38JCSYykIg_-fuPP2V3OJUyrgPQ99n26uu1fYb8apUN2NbRD39QD6UB2zl58248wevpcDK9-AVWYyji
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIuCMorUGCQoKe6xOu1Y1dCiLaJUtqEqE1Rb8vau0ZFIg44FYQr_4ffyIxfERIFLr0kUrzrR-bbmW-88wB4pm3gS2mNQ1TAONIzvhOF9EHUQYQ6SWxqOBt5OAoGJ_LNqX-6Aj_rXBgOq6x1YqGoTZbwO_IXHhEHMnYEmVezzw53jeLd1bqFRgmLA7v4Si5b_nJ_j-T7XIh-b7I7cKquAk5CZGHu2NRaMoOpTvw40p6xbuAnvpf62g-FTI2h-4uiRLi2owU9gEuDhPaCoGM5c1N6dN4rsCo9cmVasLrTG42PGt3vRUWPH_Y7HBG54W8RZZzrWGRVkVsq5BYXDxXyInt4Ed8t7F7_JtyoCCu-LhF2C1bsdA2uDqst-TXYGJfFrxebOFnmcuWbuIHjZVnsxW34MclmjAh8R0DLPi1oOo41gQzf0nJCumU8LitSY898sLhXJFDibgHhBI_L_O1tLOst55ileGR5dJ9MM8ML9dTgTmYWeHz23SL9UJZjP0uw922W8avQO3ByKcK6C61pNrX3AcMg7Xh01LpSyyRx47jL-9dEieKYWyu2oVMLQs3KSh-qDoH7qBrZKZYd-U2KvtoQ1gJTdSIrqV5F1ujfU7t_mmrzSoXkylW5UJ0i-i5iKHGwr9cVog3bzcyKJZXs5_8uu17jSjVXWi6tNjxtDpOa4b0jPbXZOY-RXS7s5IdtuFfisfmXiNIS5wnEg7-f_AlcG0yGh-pwf3TwEK4LbqRchL-vQ2v-5dw-InY3jx9XSwrh_WWv4l-vfWPn
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIlVcEJSXS4FBgp5qaq_Xr0oIQZOopbREJEW5LevddVUk4oBTQbjyr_h1zPgVIVHg0ksixbt-ZL7Z-cY7D8aeKBuFQljjIhUwrghM6KYJfiB14InS2uaGspGPjqP9E_F6Ek5W2M82F4bCKts1sVqoTaHpHflOgMQBjR1CZidvwiKGvcGL2WeXOkjRTmvbTqOGyKFdfEX3rXx-0ENZP-V80B_v7btNhwFXI3GYuza3Fk1irnSYpSow1o9CHQZ5qMKEi9wYvNc01dy3nuL4MD4O4iqIIs9SFqcI8LxX2NU4CH3SsXjSOXtekFbdfsgDcXnqJ7_FllHWY5VfhQ4qF8-ojCgXF1nGi5hvZQEHN9j1hrrCyxprN9mKna6ztaNmc36dbQ3rMtiLbRgvs7rKbdiC4bJA9uIW-zEuZoQNeI-QKz4tcDoMFcIN3qJiAd4yjOra1NA3pxZ6VSol7FVg1jCqM7l3oa68XEKRwztLowdopAlooKYGXhVmAaOz7xbwh7ow-5mG_rdZQS9Fb7OTSxHVHbY6Lab2HoMkyr0Aj1pfKKG1n2Ux7WQjOcoyarLoMK8VhJzVNT9kGwz3UXaykyQ79KAkfjksaQUm25RWXIQl2qV_T43_NNWWzWJSSl-WXHpVHF5KUKKw3yDm3GG73cyGL9U86P8uu9niSnZXWiqZwx53h3HBoV0kNbXFOY0RMZV4ChOH3a3x2P1LSG6R_UR84-8nf8TWUHflm4Pjw_vsGqeOylUc_CZbnX85tw-Q5s2zh5U-Aftw2Qr8CzLCZrc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Topical+Vancomycin+Paste+Over+the+Sternal+Edge+During+Cardiac+Surgery%3A+Effects+of+Renal+Function+and+Body+Size+on+Systemic+Exposure&rft.jtitle=Clinical+therapeutics&rft.au=Tsai%2C+Meng-Ta%2C+MD%2C+PhD&rft.au=Hu%2C+Yu-Ning%2C+MD&rft.au=Roan%2C+Jun-Neng%2C+MD%2C+PhD&rft.au=Kan%2C+Chung-Dann%2C+MD%2C+PhD&rft.date=2025-02-01&rft.issn=0149-2918&rft.volume=47&rft.issue=2&rft.spage=135&rft.epage=142&rft_id=info:doi/10.1016%2Fj.clinthera.2024.11.024&rft.externalDBID=ECK1-s2.0-S0149291824003722&rft.externalDocID=1_s2_0_S0149291824003722
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291825X00023%2Fcov150h.gif